Recurrence of clinical events at the same anatomical location in patients with MOG antibody-associated disease

Abstract

Objectives:

Likelihood of clinical events occurring within the same anatomical location in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) was retrospectively investigated.

Methods:

A total of 236 clinical events in 90 patients with MOGAD from nine referral hospitals were analyzed via logistic regression, and odds ratios (ORs) were calculated. Anatomical lesion location was divided into four groups; optic nerve, spinal cord, cerebral hemisphere, and brainstem/cerebellum.

Results:

At all locations, there was an increased likelihood of a second attack occurring at the same location as the initial event (cerebral hemisphere OR = 22.14, brainstem/cerebellum OR = 18.4, spinal cord OR = 9.1, and optic nerve OR = 7.8). There was an increased likelihood of a third attack occurring at the same location as the initial event in the optic nerve (OR = 14.9), cerebral hemisphere (OR = 11.7), and spinal cord (OR = 6.7). There were positive trends toward a third clinical event occurring at the same location as the first and/or second events if the event was in the optic nerve (OR = 13.5), cerebral hemisphere (OR = 6.9), or spinal cord (OR = 5.7).

Conclusions:

The current study suggests that clinical relapses of MOGAD during early stage tend to recur at the same anatomical locations in the central nervous system.

Keywords

Myelin oligodendrocyte glycoprotein onset location dissemination diagnosis

Get full access to this article

View all access options for this article.

References

Reindl

Waters

. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 2019; 15(2): 89–102.

Hacohen

Palace

. Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder. Neurology 2018; 90(21): 947–948.

Zamvil

Slavin

. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2015; 2(1): e62.

Mowry

Deen

Malikova

, et al. The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry 2009; 80(4): 400–403.

Zandona

Kim

Hyun

, et al. The onset location of neuromyelitis optica spectrum disorder predicts the location of subsequent relapses. Mult Scler 2014; 20(14): 1908–1911.

Kim

Hyun

Woodhall

, et al. Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases. Mult Scler Relat Disord 2020; 40: 101939.

Lee

Kim

Waters

, et al. Chronic relapsing inflammatory optic neuropathy (CRION): A manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflammation 2018; 15(1): 302.

Jurynczyk

Geraldes

Probert

, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain 2017; 140(3): 617–627.

Kitley

Waters

Woodhall

, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurol 2014; 71(3): 276–283.

10.

Lopez-Chiriboga

Majed

Fryer

, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis. JAMA Neurol 2018; 75(11): 1355–1363.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB